Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 1/20 | 0.39 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16552907 | 0.87 | ACHE (0.46) | METAP1CYP27A1CYP24A1CYP19A1ADORA2A | |
| SCHEMBL16558747 | 0.85 | P2RX7 (0.39) | METAP1CYP19A1SSTR4P2RX7 | |
| SCHEMBL16552796 | 0.80 | CYP19A1 (0.44) | METAP1CYP27A1CYP24A1CYP19A1ADORA2A | |
| SCHEMBL16552693 | 0.76 | CYP19A1 (0.58) | METAP1CYP27A1CYP24A1CYP19A1CYP26A1 | |
| SCHEMBL16558737 | 0.75 | CYP19A1 (0.37) | METAP1CYP27A1CYP24A1CYP19A1SSTR4 | |
| SCHEMBL16558745 | 0.75 | CYP19A1 (0.43) | METAP1CYP27A1CYP24A1CYP19A1SSTR4 | |
| SCHEMBL16558741 | 0.74 | HTR1A (0.38) | CYP27A1CYP24A1CYP19A1SSTR4ACHE | |
| SCHEMBL16552745 | 0.74 | ACHE (0.47) | ACHEBCHE | |
| SCHEMBL21887763 | 0.73 | EPHX2 (0.40) | CYP19A1ACHEBCHE | |
| SCHEMBL16552586 | 0.73 | ACHE (0.39) | CYP27A1CYP24A1CYP19A1ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446047-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2016-07-28 | — | — | US | disclosed |
| US-9359315-B2 | Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis | ARRIEN PHARMACEUTICALS LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | XENTHERA, INC. | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213627-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | METAP1 3605/4885CYP27A1 61/4885CYP24A1 53/4885 |
| US-20150072980-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | METAP1 3605/4885CYP27A1 61/4885CYP24A1 53/4885 |
| US-20160213676-A1 | Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis | RORA, RORB, RORC | METAP1 3605/4885CYP27A1 61/4885CYP24A1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.